LAX.SH
ABBOTT INDIA LIMITED·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
26,230
+0.42%52W Range
Market Cap
₹55,736.92 Cr
Traded: ₹22.91 Cr (0.04%) 0.0x
Free Float: ₹8,812.01 Cr (0.26% of FF traded)
Volume · 60D trend
8.78 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +10.0% | +10.0% | +9.0% | -- | +8.0% | Decelerating |
| ROE | +31.0% | +34.0% | +35.0% | -- | -- | Accelerating |
| Return | +19.0% | +10.0% | +6.0% | -18.0% | -- | Decelerating |
| Profit | +20.0% | +18.0% | +18.0% | -- | +10.0% | Stable |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,814 | 1,710 | 1,724 | 1,757 | 1,738 | 1,605 | 1,614 | 1,633 | 1,558 | 1,439 | 1,437 | 1,494 | 1,479 | 1,343 |
| Expenses | 1,291 | 1,229 | 1,261 | 1,255 | 1,293 | 1,176 | 1,178 | 1,194 | 1,167 | 1,109 | 1,049 | 1,113 | 1,124 | 1,063 |
| Operating Profit | 522 | 481 | 463 | 502 | 446 | 429 | 436 | 439 | 391 | 330 | 388 | 381 | 355 | 280 |
| OPM % | 29.0% | 28.0% | 27.0% | 29.0% | 26.0% | 27.0% | 27.0% | 27.0% | 25.0% | 23.0% | 27.0% | 25.0% | 24.0% | 21.0% |
| Other Income | 75 | 76 | 70 | 70 | 73 | 76 | 72 | 60 | 67 | 81 | 56 | 56 | 56 | 50 |
| Interest | 6 | 6 | 5 | 8 | 6 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 |
| Depreciation | 20 | 19 | 19 | 19 | 19 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 |
| Profit Before Tax | 572 | 531 | 509 | 546 | 493 | 483 | 488 | 479 | 437 | 390 | 422 | 415 | 390 | 308 |
| Tax % | 25.0% | 26.0% | 26.0% | 24.0% | 26.0% | 24.0% | 26.0% | 25.0% | 25.0% | 26.0% | 26.0% | 25.0% | 26.0% | 25.0% |
| Net Profit | 429 | 395 | 376 | 415 | 366 | 367 | 361 | 359 | 328 | 287 | 311 | 313 | 290 | 231 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 201.7 | 185.9 | 176.9 | 195.4 | 172.2 | 172.7 | 169.8 | 168.8 | 154.4 | 135.1 | 146.3 | 147.3 | 136.6 | 108.9 |
| Sales Growth (YoY) | -- | 6.5% | 6.8% | 7.6% | 11.6% | 11.5% | 12.3% | 9.3% | 5.3% | 7.1% | 8.7% | 8.3% | 13.4% | 7.0% |
| Sales Growth (QoQ) | -- | -0.8% | -1.9% | 1.1% | 8.3% | -0.6% | -1.2% | 4.8% | 8.3% | 0.1% | -3.8% | 1.0% | 10.1% | -- |
| OP Growth (YoY) | 17.0% | 12.1% | 6.2% | 14.4% | 14.1% | 30.0% | 12.4% | 15.2% | 10.1% | 17.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | 8.5% | 3.9% | -7.8% | 12.6% | 4.0% | -1.6% | -0.7% | 12.3% | 18.5% | -14.9% | 1.8% | 7.3% | 26.8% | -- |
| Profit Growth (YoY) | 17.0% | 8.0% | 4.0% | 16.0% | 12.0% | 28.0% | 16.0% | 15.0% | 13.0% | 24.0% | 26.0% | 18.0% | 41.0% | 9.0% |
| EPS Growth (YoY) | -- | 7.6% | 4.2% | 15.8% | 11.5% | 27.9% | 16.0% | 14.6% | 13.0% | 24.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 5.0% | -9.5% | 13.5% | -0.3% | 1.7% | 0.6% | 9.3% | 14.3% | -7.7% | -0.6% | 7.8% | 25.4% | -- |
| OP Margin | -- | 28.1% | 26.9% | 28.6% | 25.7% | 26.7% | 27.0% | 26.9% | 25.1% | 22.9% | 27.0% | 25.5% | 24.0% | 20.9% |
| Net Margin | -- | 23.1% | 21.8% | 23.6% | 21.1% | 22.9% | 22.4% | 22.0% | 21.1% | 19.9% | 21.6% | 20.9% | 19.6% | 17.2% |
| Material Cost % | -- | 53.0% | 53.0% | 53.0% | 54.0% | 53.0% | 55.0% | 55.0% | 54.0% | 56.0% | 54.0% | 54.0% | 56.0% | 57.0% |
| Employee Cost % | -- | 9.0% | 11.0% | 9.0% | 10.0% | 9.0% | 8.0% | 9.0% | 10.0% | 10.0% | 10.0% | 10.0% | 10.0% | 9.0% |
| P/S | 7.96 | 8.63 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 34.52 | 38.53 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 11.68 | 12.53 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Voting Results along with Consolidated Scrutinizer''s Report for the 82nd Annual General Meeting held on August 13, 2026.
Newspaper Publication
Proceedings of 82nd Annual General Meeting of the Company.
Unaudited financial results for the quarter ended June 30, 2026.
Outcome of Board Meeting
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Annual Report for the financial year 2025-26.
Submission of Business Responsibility and Sustainability Report for the Financial Year 2025-26.
Notice of the 82nd Annual General Meeting of the Company to be held on August 13, 2026.
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations , 2018 for the quarter ended June 30, 2026.
Closure of Trading Window.
Scrutinizer''s Report on Postal Ballot.
Communication to Shareholders - Intimation about Tax Deduction at Source on Dividend.
Newspaper Advertisement - Reminder to Shareholders - Unclaimed Dividends.
Appointment of Senior Management Personnel.
Annual Secretarial Compliance Report under Regulation 24A(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Newspaper Publication.
Newspaper publication.
Postal Ballot Notice - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Audited Financial Results for the quarter and year ended March 31, 2026
Outcome of Board Meeting
Record Date for Dividend
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2026 ,inter alia, to consider and approve Audited Financial Results of the ....
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.
Outcome of Board Meeting.
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.
Newspaper Advertisement - Special Window for Transfer and Dematerialisation of Physical Securities.
Closure of Trading Window
Abbott partners with Novo Nordisk India to launch Extensior, broadening access to Semaglutide (Ozempic) for advanced diabetes management.
Voting Results along with the Consolidated Scrutinizer''s Report.
Outcome of Board Meeting.
Unaudited Financial Results of the Company for the quarter ended December 31, 2025.
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve Unaudited Financial Results of ....
Newspaper Advertisement - Special Window for Transfer and Dematerialisation of Physical Securities.
Postal Ballot Notice - Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Newspaper publication of Postal Ballot Notice.
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025.
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Appointment of Mr. Vivek Mohan (DIN : 00075006) as Additional (Non-Executive) Director with effect from January 1, 2026.
Closure of Trading Window for the Unaudited Financial Results for the quarter ending on December 31, 2025.
Change in Senior Management Personnel.
Approval of Central Government for appointment of Managing Director
Newspaper Advertisement
Unaudited financial results for the quarter ended September 30, 2025.
Outcome of Board Meeting.
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve unaudited financial results for ....
Result of Postal Ballot.
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025.
Appointment of Senior Management Personnel.
Annual Reports
15Concalls
2Sep 2022
30 Sept 2022Jun 2021
30 Jun 2021Held by ETFs
30 ETFs hold ABBOTINDIA · sorted by weight
Held by Mutual Funds
82 schemes hold ABBOTINDIA · sorted by weight